Select a community
All Communities
Home > Community Treatment Reports > Memantine Treatment Report

See More Treatments

See all treatments in the PatientsLikeMe system shared by patients just like you.


Memantine Treatment Report

Brand Names: Namenda, Ebixa, Alzant

What is Memantine? Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system. It is also being tested for use as a cognitive enhancer in a variety of other conditions. Read more...Click to read more below

Merz's Memantine site


Reasons taken

67 patients in the community are taking or have taken Memantine.

Top 10 (Show all)

Dosages

Based on the patients currently taking Memantine.

  20 mg as needed daily 20 mg weekly 5 mg daily 10 mg daily 15 mg daily 20 mg daily 40 mg daily 100 mg daily 200 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 7 Number of Patients: 7 13 Number of Patients: 13 4 Number of Patients: 4 25 Number of Patients: 25 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Duration

How long current patients have been taking Memantine or how long patients were taking Memantine before stopping.

Currently Taking Memantine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
2
5
10
5
10

Stopped Taking Memantine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
3
4
0
2
2
0
Why Patients Stopped Taking Memantine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 8 73% Did not seem to work: 73%
Side effects too severe 2 18% Side effects too severe: 18%
Expense 1 9% Expense: 9%
Personal research 1 9% Personal research: 9%
Other 1 9% Other: 9%

Patient Reported Evaluations

Results from 10 patient evaluations. See the overall results and all individual evaluations.

Efficacy (Effect based on reason taken)

Major 100% 2

Other

Side-effects (as an overall problem)

Severe 0% 0
Moderate 10% 1
Mild 10% 1
None 80% 8

Top reported side-effects include: Vivid dreams, Metallic taste in mouth

Summary results are based on 10 individual responses. For more information, see overall results for Adherence, Burden and Cost.

Individual Patient Reported Evaluations (1 of 10)

  • too young!
    Sex: F
    Mouth/throat: mild
    Arms: severe
    Chest: moderate
    Legs: severe
  • too young!
  • by too young!
    Nov 07, 2009
  • EfficacyMajor
  • Side-effectsNone
  • Slow my ALS progress
Advice/Tips
has slowed progression and significantly decreased my shortness of breath through out the day, which in turn has increased my energy level. best med yet

See all evaluation results for Memantine

Report created on November 08, 2009.